Thrombocytosis in Women with Vulvar Carcinoma

Lavie, Ofer; Comerci, Giuseppe; Daras, V.; Lopes, Alberto; Monaghan, John M.

doi:10.1006/gyno.1998.5225

Cited by 31 publications

(24 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To avoid bias, four malignancies were ultimately included in our study, as endometrial, cervical, ovarian and vulvar cancer. However, only one study had evaluated the correlation between thrombocytosis and survival for patients with vulva cancer, and reported that thrombocytosis had no effect on 5-year survival rate in 201 patients with primarily surgical treatment (Lavie et al, 1999). Compared to the others, the studies about prognosis of patients with ovarian cancer lagged behind (2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012), and the earliest studies were all about cervical cancer (1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999).…”

Section: Discussionmentioning

confidence: 99%

“…Finally, 14 studies (n =3490 patients) were eligible for the meta-analysis, and 12 of the 14 reports found an inverse relationship between 5-year overall survival and thrombocytosis, that is positive studies (Hernandez et al, 1992;Lopes et al, 1994;Rodriguez et al, 1994;Gücer et al, 1998;De Jonge et al, 1999;Scholz et al, 2000; Taucher et al, 2003;Li et al, 2004;Gorelick et al, 2009;Gungor et al, 2009;Lee et al, 2011;Qiu et al, 2012;Stone et al, 2012), leaving only 2 studies negative (Hernandez et al, 1994;Lavie et al, 1999).…”

Section: Eligible Studiesmentioning

confidence: 99%

“…Begg's test and funnel was used to evaluate publication bias. No significant publication biases were found in results of meta-analyses of thrombocytosis prediction value for 5-year overall survival (p=0.870; Figure 2).We analyzed the link between thrombocytosis and the prognosis of patients in stage Ⅰ to Ⅳ (Hernandez et al, 1994;Lopes et al, 1994;Gücer et al, 1998;Lavie et al, 1999;Hernandez et al, 2000;Gungor et al, 2009;Qiu et al, 2012;Stone et al, 2012), and found the mortality was 1.76-fold higher in patients with thrombocytosis (n=1974, RR=1.76, 95% CI= [1.19-2.62], p=0.005; Figure 3A). However, the patients in stage Ⅲ to Ⅳ did not have a higher mortality (Lopes et al, 1994;Scholz et al, 2000;Li et al, 2004;Gorelick et al, 2009;Lee et al, 2011) but a much lower (n=478, RR=1.29, 95% CI= [1.13-1.48], p=0.0003; Figure 3B).…”

Section: Meta-analysi: 5-year Overall Survivalmentioning

confidence: 99%

See 2 more Smart Citations

Pretreatment Thrombocytosis as a Prognostic Factor in Women with Gynecologic Malignancies: a Meta-analysis

Liu²,

Zhang³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Eligible Studiesmentioning

confidence: 99%

Section: Meta-analysi: 5-year Overall Survivalmentioning

confidence: 99%

See 1 more Smart Citation

Pretreatment Thrombocytosis as a Prognostic Factor in Women with Gynecologic Malignancies: a Meta-analysis

Liu²,

Zhang³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Platelet count was assessed 5 days before the planned surgery. Analysis showed that platelet count was correlated with the stage of disease progression (4.46±1.00x10 11 /L vs. 3.71±9.4x10 11 /L), disease progression and a positive result of second-look surgery; it was also found to be an important predictor of the presence of metastases [5]. In the cancer patient group in the currenr staudy, in only 8 patients did thrombocythaemia precede the occurrence of the second line of the disease, whereas in patients with the platelet count <350G/L, disease progression was diagnosed in 31 cases.…”

Section: Discussionmentioning

confidence: 96%

“…Currently, there are some reports which describe more frequent occurrences of an increased blood platelet count (>400G/L) in ovarian cancer, in relation to non-malignant lesions of this organ. An increased platelet count is associated with tumours of the organs of the minor pelvis and beyond [5]. Increased thrombocytosis is found in 30-60% of patients with non-gynaecological neoplasms, and in 10-30% of patients with neoplasms of the reproductive system including ovarian cancer, vulvar cancer [6], cervical cancer and endometrial cancer [7].…”

Section: Discussionmentioning

confidence: 99%

The prognostic significance of thrombocytosis in ovarian cancer

Słabuszewska-Jóźwiak¹,

Dmoch-Gajzlerska²,

Kozakiewicz³

et al. 2015

Ann Agric Environ Med.

View full text Add to dashboard Cite

Ovarian cancer makes up 25-30% of all cases of cancers of the female genital tract. It has the highest mortality rate of any condition in oncological gynaecology. Early diagnosis is associated with a favourable 5-year survival prognosis. Many solid tumours have been detected with concomitant thrombocytosis. The tumour cell-induced platelet aggregation is a result of a direct integration of tumour cells with blood platelets. The aim of the present paper is an evaluation of platelet count as a prognostic parameter for ovarian cancer. Between 2000 -2005, 349 patients with ovarian tumour (aged 12 -88-years-old) underwent primary surgical treatment at a clinic. Ninety-seven patients with ovarian carcinomas underwent chemotherapy in the Oncology Centre. The control group comprised 252 women diagnosed with a histopathological lesion of mild intensity, whereas the cancer group constituted 97 women with a histopathologically-diagnosed malignant neoplasm. Thrombocytopaenia was assumed with a platelet count below 150G/L and thrombocythaemia at 350G/L and higher. Thrombocytosis often coincides with ascites and the cytoreduction decreases platelet count. There is a positive correlation between platelet count and tumour grading. Thrombocytosis was more frequently found in high grade tumours. There is also a positive correlation between platelet count and tumour stage according the International Federation of Gynaecology and Obstetrics (FIGO). Thrombocytosis was more frequently found in stage III and IV cancers. Patients with co-occurring thrombocytosis were found to have shorter survival periods and shorter time free from disease. This seems to give grounds for measuring platelet count before the primary surgical intervention, and suggests that the platelet count should be included in the panel of prognostic factors for patients with ovarian tumours.

show abstract

Tumor–platelet interaction in solid tumors

Buergy

Wenz

Groden

et al. 2012

Intl Journal of Cancer

318

283

View full text Add to dashboard Cite

Elevated platelet counts in patients diagnosed with malignant tumors were first described more than 100 years ago. Today it is well known that in many types of solid tumors, thrombocytosis at the time of diagnosis is associated with shorter survival. From this well-documented clinical correlation between platelet count and prognosis of solid tumors, the following questions arise: (i) Are the increased platelet counts the reason for shortened survival as platelet-secreted cytokines might boost tumor growth and angiogenesis? (ii) Do platelets affect tumor metastasis thereby shortening survival time? or (iii) Are increased platelet counts simply an epiphenomenon of tumor growth with larger tumors resulting in higher platelet counts and shorter survival times? We address these three questions within our review of the current literature to provide a comprehensive overview of the current concepts in tumor-platelet interaction.

show abstract

Thrombocytosis in Women with Vulvar Carcinoma

Cited by 31 publications

References 16 publications

Pretreatment Thrombocytosis as a Prognostic Factor in Women with Gynecologic Malignancies: a Meta-analysis

Pretreatment Thrombocytosis as a Prognostic Factor in Women with Gynecologic Malignancies: a Meta-analysis

The prognostic significance of thrombocytosis in ovarian cancer

Tumor–platelet interaction in solid tumors

Contact Info

Product

Resources

About